ERCC6L2 and leukemia: Myelodysplastic syndrome and leukemia were not reported among the six patients; however, due to the small series and the predicted functions of ERCC6L2, it is reasonable to manage these patients with a leukemia surveillance program until a leukemic risk is confidently excluded.